Friyana Bhabha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Friyana Bhabha has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Henry Miles Prince
Sir Peter MacCallum Department of Oncology University of Melbourne Parkville Victoria Australia
5 shared publications Christopher McCormack
Department of Surgical Oncology Peter MacCallum Cancer Centre Melbourne Victoria Australia
3 shared publicationsOdette Buelens
Department of Haematology Peter MacCallum Cancer Centre and Royal Melbourne Hospital Melbourne Victoria Australia
3 shared publicationsStephen Lade
Department of Pathology Peter MacCallum Cancer Centre Parkville Victoria Australia
3 shared publicationsCarrie Van Der Weyden
Department of Haematology Peter MacCallum Cancer Centre Melbourne Victoria Australia
2 shared publicationsAlicia Snowden
Epworth Healthcare East Melbourne Victoria Australia
1 shared publication
Latest Publications
- 12 September 2026
- Published by Wiley in Australasian Journal of Dermatology
The Development of Non‐Tuberculosis Mycobacterial Infections in Sézary Syndrome: A Case Report of Two Patients
Sézary syndrome (SS) is a rare cutaneous T‐cell lymphoma associated with increased risks of opportunistic and atypical infections. This report presents two patients with SS and concurrent non‐tuberculosis mycobacterial cutaneous infections. Although rare, difficult to diagnose and challenging to treat, these cases highlight the importance of considering atypical infectious causes in patients with SS.
- 12 September 2026
- Published by Wiley in Australasian Journal of Dermatology
The Development of Non‐Tuberculosis Mycobacterial Infections in Sézary Syndrome: A Case Report of Two Patients
Sézary syndrome (SS) is a rare cutaneous T‐cell lymphoma associated with increased risks of opportunistic and atypical infections. This report presents two patients with SS and concurrent non‐tuberculosis mycobacterial cutaneous infections. Although rare, difficult to diagnose and challenging to treat, these cases highlight the importance of considering atypical infectious causes in patients with SS.
- 26 May 2026
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 67 (6) , 360-363
A Case of Primary Cutaneous BRAF V600E+ Langerhans Cell Histiocytosis, With Underlying Chronic Myelomonocytic Leukaemia, Responsive to Dabrafenib With Subsequent Undetectable Circulating Cell Free DNA
We present a case of BRAF V600E+ primary cutaneous Langerhan cell histiocytosis (LCH), with corresponding circulating cell free DNA (cfDNA), which responded to treatment with dabrafenib, and simultaneously saw corresponding BRAF V600E cfDNA become undetectable. A concomitant diagnosis of chronic myelomonocytic leukaemia (CMML) was suspected with identification of TP53 , TET2 , RAS and CBL variants identified through molecular testing on the initial skin biopsy, and CMML later confirmed on bone marrow biopsy. Whilst the link between LCH and several haematological malignancies is documented, the mechanism is still unclear. In this case, the LCH most likely developed from an already abnormal myeloid compartment and highlights the need for clinical vigilance and appropriate investigation, where effective treatments for these conditions exist.
- 26 May 2026
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 67 (6) , 360-363
A Case of Primary Cutaneous BRAF V600E+ Langerhans Cell Histiocytosis, With Underlying Chronic Myelomonocytic Leukaemia, Responsive to Dabrafenib With Subsequent Undetectable Circulating Cell Free DNA
We present a case of BRAF V600E+ primary cutaneous Langerhan cell histiocytosis (LCH), with corresponding circulating cell free DNA (cfDNA), which responded to treatment with dabrafenib, and simultaneously saw corresponding BRAF V600E cfDNA become undetectable. A concomitant diagnosis of chronic myelomonocytic leukaemia (CMML) was suspected with identification of TP53 , TET2 , RAS and CBL variants identified through molecular testing on the initial skin biopsy, and CMML later confirmed on bone marrow biopsy. Whilst the link between LCH and several haematological malignancies is documented, the mechanism is still unclear. In this case, the LCH most likely developed from an already abnormal myeloid compartment and highlights the need for clinical vigilance and appropriate investigation, where effective treatments for these conditions exist.
- 21 November 2024
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 66 (1) , 32-35
Complete skin remission of Sneddon‐Wilkinson disease with acalabrutinib
Sneddon‐Wilkinson (SW) disease is rare condition which typically occurs in the context of a monoclonal immunoglobulin and treatment options have not been well studied. Here we present a case of a 65‐year‐old female with SW with underlying, otherwise indolent, lymphoplasmacytic lymphoma (LPL) with an IgA paraprotein, who achieved a complete skin remission with the administration of the Bruton Tyrosine Kinase inhibitor (BTKi), acalabrutinib.
- 21 November 2024
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 66 (1) , 32-35
Complete skin remission of Sneddon‐Wilkinson disease with acalabrutinib
Sneddon‐Wilkinson (SW) disease is rare condition which typically occurs in the context of a monoclonal immunoglobulin and treatment options have not been well studied. Here we present a case of a 65‐year‐old female with SW with underlying, otherwise indolent, lymphoplasmacytic lymphoma (LPL) with an IgA paraprotein, who achieved a complete skin remission with the administration of the Bruton Tyrosine Kinase inhibitor (BTKi), acalabrutinib.
- 9 March 2023
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 64 (2) , 194-203
CD30‐positive lymphoproliferative disorders—An Australian Clinical Practice Statement from the Peter MacCallum Cancer Centre
The CD30‐postive lymphoproliferative disorders, including lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma, account for up to 30% of all cutaneous T‐cell lymphomas (CTCLs) and are the second most common form of CTCLs after mycosis fungoides. Both conditions differ in their clinical presentations; however, they share the expression of the CD30 antigen as a common immunophenotypic hallmark. There is a wide spectrum of management options depending on factors such as extent of disease, staging and treatment tolerability. This Clinical Practice Statement is reflective of the current clinical practice in Australia.
- 9 March 2023
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 64 (2) , 194-203
CD30‐positive lymphoproliferative disorders—An Australian Clinical Practice Statement from the Peter MacCallum Cancer Centre
The CD30‐postive lymphoproliferative disorders, including lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma, account for up to 30% of all cutaneous T‐cell lymphomas (CTCLs) and are the second most common form of CTCLs after mycosis fungoides. Both conditions differ in their clinical presentations; however, they share the expression of the CD30 antigen as a common immunophenotypic hallmark. There is a wide spectrum of management options depending on factors such as extent of disease, staging and treatment tolerability. This Clinical Practice Statement is reflective of the current clinical practice in Australia.
- 26 December 2020
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 62 (1) , E8-E18
Mycosis fungoides and Sézary syndrome: Australian clinical practice statement
Primary cutaneous lymphomas represent a heterogeneous group of T‐ and B‐cell lymphomas with distinct clinical presentations, histopathologic features, treatment approaches and outcomes. The cutaneous T‐cell lymphomas, which include mycosis fungoides and Sézary syndrome, account for the majority of the cutaneous lymphomas. This Clinical Practice Statement is reflective of the current clinical practice in Australia. An expanded form of the Clinical Practice Statement (and updates), along with helpful patient resources and access to support groups, can be found at the following (http://www.australasianlymphomaalliance.org.au).
- 26 December 2020
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 62 (1) , E8-E18
Mycosis fungoides and Sézary syndrome: Australian clinical practice statement
Primary cutaneous lymphomas represent a heterogeneous group of T‐ and B‐cell lymphomas with distinct clinical presentations, histopathologic features, treatment approaches and outcomes. The cutaneous T‐cell lymphomas, which include mycosis fungoides and Sézary syndrome, account for the majority of the cutaneous lymphomas. This Clinical Practice Statement is reflective of the current clinical practice in Australia. An expanded form of the Clinical Practice Statement (and updates), along with helpful patient resources and access to support groups, can be found at the following (http://www.australasianlymphomaalliance.org.au).
- 30 December 2014
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 57 (1) , e20-2
Multiple clustered dermatofibroma presenting in a segmental distribution
Multiple dermatofibromas is a rare entity consisting of more than fifteen lesions. Multiple clustered dermatofibroma is a distinct variant of multiple dermatofibromas and is defined as a well-demarcated plaque composed of individual dermatofibromas. We report a 16-year-old boy with multiple clustered dermatofibroma in a segmental distribution, which has previously not been reported in the literature.
- 30 December 2014
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 57 (1) , e20-2
Multiple clustered dermatofibroma presenting in a segmental distribution
Multiple dermatofibromas is a rare entity consisting of more than fifteen lesions. Multiple clustered dermatofibroma is a distinct variant of multiple dermatofibromas and is defined as a well-demarcated plaque composed of individual dermatofibromas. We report a 16-year-old boy with multiple clustered dermatofibroma in a segmental distribution, which has previously not been reported in the literature.